Clinical Trials on Precocious Puberty, Gonadotropin-dependent in New Zealand

Total 7 results

Tolmar Inc.

Completed

Study of Leuprolide Acetate Injectable Suspension in the Treatment of Central Precocious Puberty

Precocious Puberty, Central

United States, Canada, Argentina, Chile, Mexico, New Zealand
University of Minnesota
Endo Pharmaceuticals; Atlantic Center for Research; Goryeb Children's Hospital

Terminated

Markers of Pubertal Suppression During Therapy for Precocious Puberty

Central Precocious Puberty

United States
AbbVie

Completed

A Study to Evaluate Leuprolide Acetate 45 mg 6-Month Formulation in Children With Central Precocious Puberty (CPP)

Central Precocious Puberty (CPP)

United States, Puerto Rico
Debiopharm International SA

Completed

Efficacy, Safety, and Pharmacokinetics (PK) of Triptorelin 6-month Formulation in Patients With Central Precocious Puberty

Central Precocious Puberty

United States, Chile, Mexico
Debiopharm International SA

Recruiting

A Study to Assess the Efficacy, Safety and Pharmacokinetics of Debio 4326 in Pediatric Participants Receiving Gonadotropin-Releasing Hormone Agonist Therapy for Central Precocious Puberty (LIBELULA)

Central Precocious Puberty

United States
AstraZeneca

Completed

Pediatrics Testotoxicosis Study [Bicalutamide Anastrozole Treatment for Testotoxicosis] (BATT)

Puberty, Precocious

United States, Canada, Russian Federation, France, India, United Kingdom
AstraZeneca

Completed

Faslodex in McCune-Albright Syndrome (FMAS)

Puberty, Precocious | McCune-Albright Syndrome

Italy, United States, Germany, France, Russian Federation, United Kingdom

Clinical Trials on Precocious Puberty, Gonadotropin-dependent in New Zealand

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Slovakia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations